| Drug radiotherapy combinations: review of previous failures and reasons for future optimism GS Higgins, SM O’Cathail, RJ Muschel, WG McKenna Cancer Treatment Reviews 41 (2), 105-113, 2015 | 94 | 2015 |
| CRISPR-Cas9 causes chromosomal instability and rearrangements in cancer cell lines, detectable by cytogenetic methods E Rayner, MA Durin, R Thomas, D Moralli, SM O'cathail, I Tomlinson, ... The CRISPR journal 2 (6), 406-416, 2019 | 59 | 2019 |
| Association of cigarette smoking with drug use and risk taking behaviour in Irish teenagers SM O'Cathail, OJ O'Connell, N Long, M Morgan, JA Eustace, BJ Plant Addictive behaviors 36 (5), 547-550, 2011 | 51 | 2011 |
| An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials DJ Pinato, C Stavraka, MJ Flynn, MD Forster, SM O'Cathail, MJ Seckl, ... PloS one 9 (1), e83279, 2014 | 48 | 2014 |
| Combining oncolytic adenovirus with radiation—a paradigm for the future of radiosensitization SM O’Cathail, TD Pokrovska, TS Maughan, KD Fisher, LW Seymour, ... Frontiers in oncology 7, 153, 2017 | 42 | 2017 |
| Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015 R Muirhead, K Drinkwater, SM O'Cathail, R Adams, R Glynne-Jones, ... Clinical Oncology 29 (3), 188-197, 2017 | 40 | 2017 |
| A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally … SM O’Cathail, S Davis, J Holmes, R Brown, K Fisher, L Seymour, ... Radiation Oncology 15, 1-8, 2020 | 23 | 2020 |
| Activity of eribulin mesylate in heavily pretreated breast cancer granted accessvia the Cancer Drugs Fund R Ramaswami, SM O’Cathail, JH Brindley, P Silcocks, S Mahmoud, ... Future Oncology 10 (3), 363-376, 2014 | 19 | 2014 |
| Developing an objective marker to optimize patient selection and predict survival benefit in early‐phase cancer trials C Stavraka, DJ Pinato, SJ Turnbull, MJ Flynn, MD Forster, SM O'Cathail, ... Cancer 120 (2), 262-270, 2014 | 18 | 2014 |
| Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies SM O’Cathail, R Shaboodien, S Mahmoud, K Carty, P O’Sullivan, ... International Journal of Gynecologic Cancer 23 (7), 2013 | 17 | 2013 |
| Intensity-modulated radiotherapy for rectal cancer in the UK in 2020 CR Hanna, F Slevin, A Appelt, M Beavon, R Adams, C Arthur, M Beasley, ... Clinical Oncology 33 (4), 214-223, 2021 | 14 | 2021 |
| Stereotactic body radiation therapy reirradiation for locally recurrent rectal cancer: outcomes and toxicity T Smith, SM O’Cathail, S Silverman, M Robinson, Y Tsang, M Harrison, ... Advances in Radiation Oncology 5 (6), 1311-1319, 2020 | 13 | 2020 |
| Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT) CR Hanna, SM O’Cathail, JS Graham, M Saunders, L Samuel, M Harrison, ... Radiation Oncology 16, 1-9, 2021 | 12 | 2021 |
| Update on neoadjuvant regimens for patients with operable oesophageal/gastrooesophageal junction adenocarcinomas and squamous cell carcinomas SJ Cox, SM O’Cathail, B Coles, T Crosby, S Mukherjee Current oncology reports 19, 1-11, 2017 | 12 | 2017 |
| Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy SM O'Cathail, T Smith, R Owens, A Zeniou, Y Tsang, DLP Holyoake, ... Radiotherapy and Oncology 151, 280-286, 2020 | 11 | 2020 |
| Challenges and consequences of COVID-19 in the management of anorectal cancer: coming together through social distancing SM O'Cathail, DC Gilbert, D Sebag-Montefiore, R Muirhead Clinical Oncology 32 (7), 413-416, 2020 | 11 | 2020 |
| NRF2 mediates therapeutic resistance to chemoradiation in colorectal cancer through a metabolic switch SM O’Cathail, CH Wu, R Thomas, MA Hawkins, TS Maughan, A Lewis Antioxidants 10 (9), 1380, 2021 | 10 | 2021 |
| NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer SM O'Cathail, CH Wu, A Lewis, C Holmes, MA Hawkins, T Maughan Cancer Genetics 248, 1-10, 2020 | 10 | 2020 |
| Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes R Cooke, P Camilleri, KY Chu, SM O'Cathail, M Robinson, ... Technical Innovations & Patient Support in Radiation Oncology 13, 24-30, 2020 | 10 | 2020 |
| A multicentre retrospective review of SABR reirradiation in rectal cancer recurrence P Johnstone, L Okonta, K Aitken, J Holmes, M Harrison, D Harji, ... Radiotherapy and Oncology 162, 1-6, 2021 | 8 | 2021 |
Annabelle LewisLecturer in Biomedical Sciences, Brunel University, LondonVerified email at brunel.ac.uk
